The DOI matches its Crossref record.
Antiretroviral drugs and the central nervous system
Abstract
Introduction With potent antiretroviral drug combinations it is possible to reduce the number of HIV RNA copies in plasma to undetectable levels [1]. Persistent low levels of HIV RNA in plasma are correlated with an improved prognosis [2]. However, for several sites in the infected host, it is as yet unclear how efficacious combination treatment is in suppressing viral replication. One of these sanctuary sites is the central nervous system (CNS). The presence of HIV and the level of HIV replication in the brain parenchyma are difficult to study, and we have to rely on post-mortem examination of brain tissue, animal studies, and cerebrospinal fluid (CSF) levels of HIV RNA. For clinical practice, CSF viral load measurements are relatively easy to obtain and are potentially useful. HIV RNA is detectable in the CSF of most HIV-infected individuals. The CSF HIV load varies widely (median, 3 log10 copies/ml; range, 0–6 log10 copies/ml), but is generally lower than the plasma viral load [3–10]. Patients in whom CSF viral load has exceeded plasma viral load have been reported [5,11–14]. Conflicting results have been found in the correlation between plasma and CSF viral load. In many studies a positive correlation has been noted [4,8,10,15–17], but in others no correlation was found [5–7,9,13,14,18]. A further intriguing finding is that in several studies a correlation was found between CSF viral load and the extent of damage to the blood—CSF barrier or CSF white cell count [12,14,15,19], whereas in others this correlation has been disputed [3,6,7,20]. Different study populations and the influence of antiretroviral therapy may explain some of these differences. Several groups of patients can be described (Table 1). The first group consists of patients with low CD4 cell counts and CNS opportunistic infections (e.g., patients with cryptococcal meningitis usually have high CSF viral loads) [6,14]. An elevated CSF white cell count probably contributes to this increased level of HIV replication [6,14]. A second group consists of patients with low CD4 cell counts and AIDS dementia complex or HIV encephalitis. In these patients, CSF HIV load probably reflects increased CNS (but not plasma) viral replication [6,13]. High CSF viral loads correlate with the presence and degree of cognitive impairment [3,6,9,10] or neuropathological abnormalities [13]. Furthermore, a correlation has been found between brain and CSF levels of HIV RNA in patients with AIDS dementia [10]. The third and largest group comprises neurologically asymptomatic patients who may have detectable CSF viral loads [8,9,12,21].Table 1: . Cerebrospinal fluid (CSF) viral load studies.The CSF viral load increases with decreasing CD4 cell count [10]. In antiretroviral-naive patients, viral replication within the plasma and CSF compartments occurs independently [12]. To our knowledge, no data are available on CSF viral RNA in patients with primary HIV infection. It is, however, known that HIV can be cultured from the CSF (and not from the blood) during seroconversion [22,23]. HIV antigen can sometimes be detected in the CSF (before it is present in the blood) from such patients [24]. HIV load within the brain parenchyma can only be determined by post-mortem examination. In two studies [10,25], brain tissue was examined for the presence of viral RNA. In the first study, HIV RNA could be detected in 50% of the examined brains [25]. Quantitative data were given in another study, but non-demented patients did not differ from demented patients [10]. Although provirus was detected in the brain of one patient who had been infected 15 days earlier, generally no substantial amounts of provirus could be detected in asymptomatic patients. In most patients with AIDS, proviral DNA has been found, with the highest levels in patients with HIV encephalitis [26–29]. Does antiretroviral treatment suppress HIV replication in the CNS? Patients with HIV dementia may improve with zidovudine (ZDV) treatment, and the widespread use of ZDV has contributed to the decrease in the incidence of HIV dementia [30–32]. HIV-specific neuropathological abnormalities are less frequent in patients who used ZDV until death, compared with patients who discontinued the drug 1 month (or earlier) before death [33]. CSF viral load was reduced in most patients after the start of ZDV monotherapy [34]. These data suggest that ZDV suppresses HIV replication within the CNS. Data for all the other antiretroviral drugs are sparse. Reduction of CSF viral load has been observed in some patients on didanosine (ddI) monotherapy [34]. In several nucleoside-containing combination studies, CSF viral load has been reported to be reduced to undetectable levels [8,12,35,36]. In one study using ultrasensitive quantitative PCR, the viral load decreased to values below 20 copies/ml [21]. In two patients who had been given triple therapy, the decrease in CSF viral load lagged behind the decrease in plasma viral load [37]. Riton
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pathways to neuronal injury and apoptosis in HIV-associated dementia
Kaul, M., Garden, G. A., & Lipton, S. A. (2001) · Nature · doi:10.1038/35073667 · Cited by 1,210
The prevalence and incidence of neurocognitive impairment in the HAART era
Robertson, K. R., Smurzynski, M., Parsons, T. D., Wu, K., Bosch, R. J., Wu, J., McArthur, J. C., Collier, A. C., Evans, S. R., & Ellis, R. J. (2007) · AIDS · doi:10.1097/qad.0b013e32828e4e27 · Cited by 619
Drug Transporters in the Central Nervous System: Brain Barriers and Brain Parenchyma Considerations
Lee, G., Dallas, S., Hong, M., & Bendayan, R. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01513-8 · Cited by 539
Nanotechnological advances for the delivery of cns therapeutics.
Wong, H. L., Wu, X. Y., & Bendayan, R. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.10.007 · Cited by 488
Dornadula, G. (1999) · JAMA · doi:10.1001/jama.282.17.1627 · Cited by 463
Metadata
- Authors
- Enting, R. H., Hoetelmans, R. M. W., Lange, J. M. A., Burger, D. M., Beijnen, J. H., & Portegies, P.
- Venue
- AIDS
- Published
- 1998-10
- Volume
- 12
- Issue
- 15
- Pages
- 1941-1955
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2326389129
- Cited by
- 188
- References
- 0
- FWCI
- 4.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiretroviral drugs and the central nervous system. https://app.cochat.ai/papers/10.1097/00002030-199815000-00005
- The paper
- Enting, R. H., Hoetelmans, R. M. W., Lange, J. M. A., Burger, D. M., Beijnen, J. H., & Portegies, P. (1998). Antiretroviral drugs and the central nervous system. AIDS. https://doi.org/10.1097/00002030-199815000-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.